Por favor, use este identificador para citar o enlazar este ítem: http://www.alice.cnptia.embrapa.br/alice/handle/doc/1146721
Registro completo de metadatos
Campo DCValorLengua/Idioma
dc.contributor.authorMADRID, R. R. M
dc.contributor.authorMATHEWS, P. D.
dc.contributor.authorPATTA, A. C. F.
dc.contributor.authorGONZALES-FLORES, A. P.
dc.contributor.authorRAMIREZ. C. A. B.
dc.contributor.authorRIGONI, V. L. S.
dc.contributor.authorTAVARES-DIAS, M.
dc.contributor.authorMERTINS, O.
dc.date.accessioned2023-04-13T15:09:39Z-
dc.date.available2023-04-13T15:09:39Z-
dc.date.created2022-09-22
dc.date.issued2021
dc.identifier.citationHeliyon, v. 7, n. 1, e05820, Jan. 2021.
dc.identifier.urihttp://www.alice.cnptia.embrapa.br/alice/handle/doc/1146721-
dc.descriptionThe FDA-approved drug ivermectin is applied for treatments of onchocerciasis and lymphatic filariasis. The anticancer and anti-viral activities have been demonstrated stressing possibilities for the drug repurposing and therefore new information on high dosage safety is on demand. We analyzed in vivo tissue responses for high doses of ivermectin using Corydoras fish as animal model. We made intestinal histology and hematologic assays after oral administration of ivermectin transported with polyelectrolytes formulation. Histology showed any apparent damage of intestinal tissues at 0.22?170 mg of ivermectin/kg body weight. Immunofluorescence evidenced delocalization of Myosin-Vb at enterocytes only for the higher dose. Hematology parameters showed random variations after 7 days from administration, but a later apparent recover after 14 and 21 days. The study evaluated the potential of high doses of oral administration of ivermectin formulation, which could be an alternative with benefits in high compliance therapies.
dc.language.isoeng
dc.rightsopenAccess
dc.titleSafety of oral administration of high doses of ivermectin by means of biocompatible polyelectrolytes formulation.
dc.typeArtigo de periódico
dc.subject.thesagroPeixe
dc.subject.nalthesaurusCorydoras
dc.subject.nalthesaurusIvermectin
riaa.ainfo.id1146721
riaa.ainfo.lastupdate2022-12-14
dc.identifier.doihttps://doi.org/10.1016/j.heliyon.2020.e05820
dc.contributor.institutionRAFAEL R. M. MADRID, UNIVERSIDADE FEDERAL DE SÃO PAULO; PATRICK D. MATHEWS, UNIVERSIDADE FEDERAL DE SÃO PAULO; ANA C. M. F. PATTA, UNIVERSIDADE FEDERAL DE SÃO PAULO; ANAI P. GONZALES-FLORES, INSTITUTE OF RESEARCH OF THE PERUVIAN AMAZON; CARLOS A. B. RAMIREZ, UNIVERSIDADE FEDERAL DE SÃO PAULO; VERA L. S. RIGONI, UNIVERSIDADE FEDERAL DE SÃO PAULO; MARCOS TAVARES DIAS, CPAF-AP; OMAR MERTINS, UNIVERSIDADE FEDERAL DE SÃO PAULO.
Aparece en las colecciones:Artigo em periódico indexado (CPAF-AP)

Ficheros en este ítem:
Fichero Descripción TamañoFormato 
CPAF-AP-2022-Safety-of-oral-administration-of-high-doses-of-ivermectin.pdf1.18 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro sencillo del ítem

FacebookTwitterDeliciousLinkedInGoogle BookmarksMySpace